Concepedia

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

Helga Hagman, Jan‐Erik Frödin, Åke Berglund, J. Sundberg, L.W. Vestermark, M. Albertsson, Eva Fernebro, Anna Johnsson

Annals of Oncology · 2015 · 57 citations · 12 references

DOIFull text

Open access

Concepts

References

12

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text

, , +17

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Eric Van Cutsem, Andrés Cervantes, Bernard Nordlinger et al. · Annals of Oncology · 2014 · 1.2K citations

, , +14

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Lieke H. J. Simkens, Harm van Tinteren, Anne M. May et al. · The Lancet · 2015 · 528 citations

, , +13

Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II Study

Eric Van Cutsem, Michael Findlay, B Osterwalder et al. · Journal of Clinical Oncology · 2000 · 322 citations

, , +16

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

Susanna Hegewisch‐Becker, Ullrich Graeven, Christian Lerchenmüller et al. · The Lancet Oncology · 2015 · 251 citations

, , +12